By Ludwig Burger (Reuters) -Swiss drugmaker Roche is petitioning the U.S. government in direct talks for import tariff exemptions, arguing the products it ships into the United States are offset by its exports of U.

Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., according to CEO Thomas Schinecker, who declined to reveal what these assets are.

Roche is pledging to invest $50 billion in manufacturing and research infrastructure in the U.S. over the next five years, making the pharmaceutical giant the latest company to unveil a capital expenditure push as drugmakers prepare for expected tariffs from the Trump administration.